Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron‐induced hepatotoxicity

• Published in: Hepatology (Baltimore, Md.) Vol. 76; no. 2; pp. 387 - 403
• Main Authors: Xiong, Hui, Zhang, Chunze, Han, Lifeng, Xu, Tong, Saeed, Khawar, Han, Jing, Liu, Jing, Klaassen, Curtis D., Gonzalez, Frank J., Lu, Yuanfu, Zhang, Youcai
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc 01.08.2022
• Subjects: Agonists; Ammonium; Bile; Bile acids; Blood diseases; Dextran; Diet; Fatty liver; Ferrous sulfate; Fibroblast growth factors; Hepatocytes; Hepatology; Hepatotoxicity; Homeostasis; Iron; Iron deficiency; Liver diseases; Metabolic syndrome; Nutrient deficiency; Oral administration; Regulatory proteins; Serum levels; Steatosis; Thalassemia
• ISSN: 0270-9139; 1527-3350; 1527-3350
• DOI: 10.1002/hep.32270

Background and Aims Iron overload (IO) is a frequent finding in the general population. As the major iron storage site, the liver is subject to iron toxicity. Farnesoid X receptor (FXR) regulates bile acid metabolism and is implicated in various liver diseases. We aimed to determine whether FXR plays a role in regulating iron hepatotoxicity. Approach and Results Human and mouse hepatocytes were treated with ferric ammonium citrate or iron dextran (FeDx). Mice were orally administered ferrous sulfate or injected i.p. with FeDx. Wild‐type and Fxr−/− mice were fed an iron‐rich diet for 1 or 5 weeks. Mice fed an iron‐rich diet were coadministered the FXR agonist, GW4064. Forced expression of FXR was carried out with recombinant adeno‐associated virus 1 week before iron‐rich diet feeding. Serum levels of bile acids and fibroblast growth factor 19 (FGF19) were quantified in adults with hyperferritinemia and children with β‐thalassemia. The data demonstrated that iron suppressed FXR expression and signaling in human and mouse hepatocytes as well as in mouse liver and intestine. FXR deficiency potentiated iron hepatotoxicity, accompanied with hepatic steatosis as well as dysregulated iron and bile acid homeostasis. FXR negatively regulated iron‐regulatory proteins 1 and 2 and prevented hepatic iron accumulation. Forced FXR expression and ligand activation significantly suppressed iron hepatotoxicity in iron‐fed mice. The FXR agonist, GW4064, almost completely restored dysregulated bile acid signaling and metabolic syndrome in iron‐fed mice. Conjugated primary bile acids were increased and FGF19 was decreased in serum of adults with hyperferritinemia and children with β‐thalassemia. Conclusions FXR plays a pivotal role in regulating iron homeostasis and protects mice against iron hepatotoxicity. Targeting FXR may represent a therapeutic strategy for IO‐associated chronic liver diseases.